Geron (GERN) Competitors

$1.39 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$1.40 +0.01 (+0.36%)

As of 05:19 PM Eastern

GERN vs. ALKS, BCRX, CLDX, INVA, and NVAX

Should you be buying Geron stock or one of its competitors? The main competitors of Geron include Alkermes (ALKS), BioCryst Pharmaceuticals (BCRX), Celldex Therapeutics (CLDX), Innoviva (INVA), and Novavax (NVAX). These companies are all part of the "biotechnology" industry.

How does Geron compare to Alkermes?

Geron (NASDAQ:GERN) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk.

Geron currently has a consensus target price of $2.50, indicating a potential upside of 79.86%. Alkermes has a consensus target price of $45.21, indicating a potential upside of 27.47%. Given Geron's higher possible upside, analysts clearly believe Geron is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Geron	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Alkermes	0 Sell rating(s)	5 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.82

In the previous week, Alkermes had 4 more articles in the media than Geron. MarketBeat recorded 25 mentions for Alkermes and 21 mentions for Geron. Alkermes' average media sentiment score of 0.65 beat Geron's score of 0.43 indicating that Alkermes is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Geron	2 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alkermes	8 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Geron has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500. Comparatively, Alkermes has a beta of 0.31, meaning that its stock price is 69% less volatile than the S&P 500.

73.7% of Geron shares are owned by institutional investors. Comparatively, 95.2% of Alkermes shares are owned by institutional investors. 1.7% of Geron shares are owned by company insiders. Comparatively, 4.6% of Alkermes shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Alkermes has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Geron	$183.88M	4.85	-$83.50M	-$0.11	N/A
Alkermes	$1.48B	4.01	$241.66M	$0.90	39.41

Alkermes has a net margin of 9.78% compared to Geron's net margin of -35.48%. Alkermes' return on equity of 9.26% beat Geron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Geron	-35.48%	-23.31%	-10.08%
Alkermes	9.78%	9.26%	5.66%

Summary

Alkermes beats Geron on 14 of the 17 factors compared between the two stocks.

How does Geron compare to BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Geron (NASDAQ:GERN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.

BioCryst Pharmaceuticals presently has a consensus target price of $20.70, indicating a potential upside of 141.26%. Geron has a consensus target price of $2.50, indicating a potential upside of 79.86%. Given BioCryst Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe BioCryst Pharmaceuticals is more favorable than Geron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.75
Geron	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, BioCryst Pharmaceuticals had 2 more articles in the media than Geron. MarketBeat recorded 23 mentions for BioCryst Pharmaceuticals and 21 mentions for Geron. Geron's average media sentiment score of 0.43 beat BioCryst Pharmaceuticals' score of 0.04 indicating that Geron is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioCryst Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral
Geron	2 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioCryst Pharmaceuticals has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500. Comparatively, Geron has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500.

85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 73.7% of Geron shares are held by institutional investors. 5.1% of BioCryst Pharmaceuticals shares are held by insiders. Comparatively, 1.7% of Geron shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

BioCryst Pharmaceuticals has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals	$885.72M	2.46	$263.86M	-$1.78	N/A
Geron	$183.88M	4.85	-$83.50M	-$0.11	N/A

Geron has a net margin of -35.48% compared to BioCryst Pharmaceuticals' net margin of -51.71%. Geron's return on equity of -23.31% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%
Geron	-35.48%	-23.31%	-10.08%

Summary

BioCryst Pharmaceuticals beats Geron on 10 of the 16 factors compared between the two stocks.

How does Geron compare to Celldex Therapeutics?

Celldex Therapeutics (NASDAQ:CLDX) and Geron (NASDAQ:GERN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability.

Geron has higher revenue and earnings than Celldex Therapeutics. Geron is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics	$1.54M	1,645.23	-$258.76M	-$4.26	N/A
Geron	$183.88M	4.85	-$83.50M	-$0.11	N/A

Celldex Therapeutics has a net margin of 0.00% compared to Geron's net margin of -35.48%. Geron's return on equity of -23.31% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics	N/A	-50.72%	-46.59%
Geron	-35.48%	-23.31%	-10.08%

73.7% of Geron shares are owned by institutional investors. 5.2% of Celldex Therapeutics shares are owned by insiders. Comparatively, 1.7% of Geron shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Geron had 10 more articles in the media than Celldex Therapeutics. MarketBeat recorded 21 mentions for Geron and 11 mentions for Celldex Therapeutics. Geron's average media sentiment score of 0.43 beat Celldex Therapeutics' score of 0.10 indicating that Geron is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celldex Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Geron	2 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Celldex Therapeutics has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500. Comparatively, Geron has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500.

Celldex Therapeutics presently has a consensus target price of $48.00, indicating a potential upside of 48.70%. Geron has a consensus target price of $2.50, indicating a potential upside of 79.86%. Given Geron's higher possible upside, analysts clearly believe Geron is more favorable than Celldex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Geron	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Geron beats Celldex Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Geron compare to Innoviva?

Geron (NASDAQ:GERN) and Innoviva (NASDAQ:INVA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends, profitability and media sentiment.

Innoviva has a net margin of 119.89% compared to Geron's net margin of -35.48%. Innoviva's return on equity of 33.33% beat Geron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Geron	-35.48%	-23.31%	-10.08%
Innoviva	119.89%	33.33%	22.67%

In the previous week, Geron had 12 more articles in the media than Innoviva. MarketBeat recorded 21 mentions for Geron and 9 mentions for Innoviva. Innoviva's average media sentiment score of 1.17 beat Geron's score of 0.43 indicating that Innoviva is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Geron	2 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Innoviva	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Geron has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. Comparatively, Innoviva has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500.

Innoviva has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Geron	$183.88M	4.85	-$83.50M	-$0.11	N/A
Innoviva	$411.33M	4.06	$271.17M	$6.01	3.75

73.7% of Geron shares are owned by institutional investors. Comparatively, 99.1% of Innoviva shares are owned by institutional investors. 1.7% of Geron shares are owned by insiders. Comparatively, 2.0% of Innoviva shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Geron presently has a consensus target price of $2.50, indicating a potential upside of 79.86%. Innoviva has a consensus target price of $36.20, indicating a potential upside of 60.75%. Given Geron's higher possible upside, equities research analysts plainly believe Geron is more favorable than Innoviva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Geron	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Innoviva beats Geron on 12 of the 16 factors compared between the two stocks.

How does Geron compare to Novavax?

Geron (NASDAQ:GERN) and Novavax (NASDAQ:NVAX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

In the previous week, Novavax had 22 more articles in the media than Geron. MarketBeat recorded 43 mentions for Novavax and 21 mentions for Geron. Novavax's average media sentiment score of 0.68 beat Geron's score of 0.43 indicating that Novavax is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Geron	2 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Novavax	18 Very Positive mention(s)	6 Positive mention(s)	11 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Positive

Geron has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500. Comparatively, Novavax has a beta of 2.37, meaning that its stock price is 137% more volatile than the S&P 500.

73.7% of Geron shares are held by institutional investors. Comparatively, 53.0% of Novavax shares are held by institutional investors. 1.7% of Geron shares are held by company insiders. Comparatively, 1.0% of Novavax shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Geron currently has a consensus target price of $2.50, suggesting a potential upside of 79.86%. Novavax has a consensus target price of $12.13, suggesting a potential upside of 27.63%. Given Geron's higher probable upside, analysts plainly believe Geron is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Geron	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Novavax	4 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.10

Novavax has a net margin of -14.73% compared to Geron's net margin of -35.48%. Novavax's return on equity of -14.82% beat Geron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Geron	-35.48%	-23.31%	-10.08%
Novavax	-14.73%	-14.82%	1.23%

Novavax has higher revenue and earnings than Geron. Novavax is trading at a lower price-to-earnings ratio than Geron, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Geron	$183.88M	4.85	-$83.50M	-$0.11	N/A
Novavax	$1.12B	1.39	$440.30M	-$0.58	N/A

Summary

Novavax beats Geron on 10 of the 16 factors compared between the two stocks.

Get Geron News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GERN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GERN vs. The Competition

Export

Metric	Geron	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$891.71M	$3.37B	$6.18B	$12.27B
Dividend Yield	N/A	2.24%	2.78%	5.22%
P/E Ratio	-12.64	15.19	20.66	25.70
Price / Sales	4.85	194.53	527.64	64.90
Price / Cash	N/A	56.93	27.81	36.27
Price / Book	3.97	6.94	9.77	6.74
Net Income	-$83.50M	$24.11M	$3.54B	$333.09M
7 Day Performance	N/A	N/A	N/A	0.52%
1 Month Performance	-16.77%	4.63%	6.28%	8.98%
1 Year Performance	17.30%	78.21%	41.81%	42.45%

Geron Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GERN Geron	2.2118 of 5 stars	$1.39 flat	$2.50 +79.9%	+16.9%	$891.71M	$183.88M	N/A	70	Earnings Report Analyst Revision
ALKS Alkermes	3.2758 of 5 stars	$33.71 flat	$44.07 +30.7%	+16.1%	$5.60B	$1.48B	23.57	2,050
BCRX BioCryst Pharmaceuticals	3.6782 of 5 stars	$9.16 +1.9%	$19.64 +114.4%	-13.6%	$2.28B	$874.84M	7.63	530	Earnings Report Analyst Downgrade
CLDX Celldex Therapeutics	2.6095 of 5 stars	$32.88 +2.3%	$46.36 +41.0%	+85.3%	$2.14B	$1.54M	N/A	150	Earnings Report Analyst Forecast
INVA Innoviva	3.9798 of 5 stars	$22.99 -0.3%	$34.80 +51.4%	+23.3%	$1.71B	$411.33M	7.54	100	Positive News Earnings Report Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GERN) was last updated on 5/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Geron (GERN) Competitors